<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528305</url>
  </required_header>
  <id_info>
    <org_study_id>2015CM</org_study_id>
    <nct_id>NCT02528305</nct_id>
  </id_info>
  <brief_title>The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis</brief_title>
  <official_title>A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bath</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abertay University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bath</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval
      Training (HIT) results in improvements in disease-specific measures, feelings of general
      well-being, physical fitness and cognitive function in patients with non-alcoholic fatty
      liver disease or non-alcoholic steatohepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to recruit up to 12 patients diagnosed with non-alcoholic fatty liver disease
      (NAFLD) or non-alcoholic steatohepatitis (NASH) from the liver clinics at Ninewells Hospital,
      Dundee. Suitable patients who give informed consent will be assessed at baseline, again after
      6 weeks of no intervention to act as a control period, and thirdly after 6 weeks of
      twice-weekly high-intensity interval training (HIT).

      Assessments will be performed with the patient fasted overnight, and will involve body
      composition measurements, blood pressure, a venous blood sample for circulating
      triglycerides, fasting glucose, insulin, liver enzymes alanine aminotransferase (ALT) and
      aspartate aminotransferase (AST), and platelets. An oral glucose tolerance test will be
      performed using fingerprick capillary samples. Cognitive function tests for episodic memory,
      executive function and semantic memory will be performed and a questionnaire (SF-36) will be
      used to assess general well-being. Physical fitness will be assessed through a 12-minute walk
      test on a treadmill, which will allow estimation of maximal oxygen uptake capacity (VO2 max),
      and a &quot;get up and go&quot; test will be used to assess physical function.

      The exercise intervention will involve a 2 minute warm-up, cycling at 50 rpm before the
      participants will be asked to cycle at 100rpm and a weight will be added (7% body weight for
      men and 6% body weight for women) as resistance. The sprint will last 6 seconds and the
      participant will be asked to rest for at least 1 minute. This will be repeated for a total of
      5 sprints in sessions 1-3, 6 sprints in session 4, 7 sprints in sessions 5&amp;6, 8 sprints in
      sessions 7&amp;8, 9 sprints in sessions 9&amp;10 and 10 sprints in sessions 11&amp;12. Exercise heart
      rate will be monitored and recorded.

      At least 3 days after the last HIT session the pre-intervention testing assessment will be
      repeated for a third time.

      Changes in measured variables will be analysed via repeated measures analysis of variance
      (ANOVA) with post-hoc testing of all variables.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No Masking, this was not possible with this study design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score &lt;3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score &gt;5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Glucose Tolerance Test</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AST: ALT Ratio</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT).
used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1.
Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FIB-4</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver.
Fib-4 score of &lt;1.45 has negative predictive value of 90% for advanced fibrosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Fat Mass Estimated Via Bioimpedance</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>taken with participant supine, measured on left arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General Well-being as Assessed by SF-36 Questionnaire</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Memory Recall</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated VO2 Max</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Function-&quot;Get up and go&quot; Test</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ankle Brachial Pressure Index (ABPI)</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>ratio of blood pressure in left arm and right ankle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Memory Recall</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds).
Maximum= 10 words, minimum = no words</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Executive Function (Verbal Fluency Test)</measure>
    <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
    <description>written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals.
Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>High-intensity Interval Training (HIT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 week control period with no intervention then 6 weeks of twice weekly HIT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-intensity Interval Training</intervention_name>
    <description>2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&amp;6, 8 sprints in sessions 7&amp;8, 9 sprints in sessions 9&amp;10 and 10 sprints in sessions 11&amp;12.</description>
    <arm_group_label>High-intensity Interval Training (HIT)</arm_group_label>
    <other_name>Exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of non-alcoholic fatty liver disease or non-alcoholic
             steatohepatitis

          -  attending a specialist liver clinic at Ninewells Hospital, Dundee

        Exclusion Criteria:

          -  unstable cardiovascular disease

          -  uncontrolled arrhythmias

          -  structural cardiac abnormalities

          -  uncontrolled diabetes

          -  other uncontrolled metabolic abnormalities

          -  severe orthopaedic condition that would prohibit exercise

          -  severe pulmonary condition that would prohibit exercise

          -  any other poorly controlled medical condition.

          -  resting systolic blood pressure above 160 mm Hg

          -  resting diastolic blood pressure above 90 mm Hg

          -  symptomatic postural drop in blood pressure greater than 20 mm Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels BJ Vollaard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bath</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abertay University</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 1HG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <results_first_submitted>December 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2018</results_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bath</investigator_affiliation>
    <investigator_full_name>Niels Vollaard</investigator_full_name>
    <investigator_title>Lecturer in Human and Applied Physiology</investigator_title>
  </responsible_party>
  <keyword>High-intensity Interval Training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no reason to share the IPD.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-intensity Interval Training (HIT)</title>
          <description>6 week control period with no intervention then 6 weeks of twice weekly HIT
High-intensity Interval Training: 2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&amp;6, 8 sprints in sessions 7&amp;8, 9 sprints in sessions 9&amp;10 and 10 sprints in sessions 11&amp;12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Control Period Assessment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Intervention Period Assessment</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-intensity Interval Training (HIT)</title>
          <description>6 week control period with no intervention then 6 weeks of twice weekly HIT
High-intensity Interval Training: 2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&amp;6, 8 sprints in sessions 7&amp;8, 9 sprints in sessions 9&amp;10 and 10 sprints in sessions 11&amp;12.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>metres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.71" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-alcoholic Fatty Liver Disease (NAFLD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-alcoholic Steatohepatitis (NASH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score &lt;3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score &gt;5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score &lt;3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score &gt;5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="4.7"/>
                    <measurement group_id="O2" value="9.6" spread="10.5"/>
                    <measurement group_id="O3" value="7.0" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.474</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Glucose Tolerance Test</title>
        <description>measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments.</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance Test</title>
          <description>measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments.</description>
          <units>mmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="981" spread="136"/>
                    <measurement group_id="O2" value="1030" spread="182"/>
                    <measurement group_id="O3" value="1010" spread="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AST: ALT Ratio</title>
        <description>ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT).
used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1.
Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis.</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>AST: ALT Ratio</title>
          <description>ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT).
used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1.
Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.5" spread="0.2"/>
                    <measurement group_id="O3" value="0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FIB-4</title>
        <description>calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver.
Fib-4 score of &lt;1.45 has negative predictive value of 90% for advanced fibrosis.</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>FIB-4</title>
          <description>calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver.
Fib-4 score of &lt;1.45 has negative predictive value of 90% for advanced fibrosis.</description>
          <units>Fibrosis Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.18"/>
                    <measurement group_id="O2" value="0.60" spread="0.19"/>
                    <measurement group_id="O3" value="0.60" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Fat Mass Estimated Via Bioimpedance</title>
        <description>total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Body Fat Mass Estimated Via Bioimpedance</title>
          <description>total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage</description>
          <units>percentage body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="8.2"/>
                    <measurement group_id="O2" value="29.5" spread="8.3"/>
                    <measurement group_id="O3" value="28.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>trunk fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="6.0"/>
                    <measurement group_id="O2" value="29.1" spread="5.4"/>
                    <measurement group_id="O3" value="28.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Total body fat</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.101</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Trunk fat</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>taken with participant supine, measured on left arm</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>taken with participant supine, measured on left arm</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="18"/>
                    <measurement group_id="O2" value="142" spread="13"/>
                    <measurement group_id="O3" value="136" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="13"/>
                    <measurement group_id="O2" value="87" spread="10"/>
                    <measurement group_id="O3" value="78" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of systolic blood pressure</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of diastolic blood pressure</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>General Well-being as Assessed by SF-36 Questionnaire</title>
        <description>Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>General Well-being as Assessed by SF-36 Questionnaire</title>
          <description>Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="25"/>
                    <measurement group_id="O2" value="85" spread="22"/>
                    <measurement group_id="O3" value="92" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="31"/>
                    <measurement group_id="O2" value="82" spread="27"/>
                    <measurement group_id="O3" value="83" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="17"/>
                    <measurement group_id="O2" value="69" spread="20"/>
                    <measurement group_id="O3" value="77" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="13"/>
                    <measurement group_id="O2" value="72" spread="28"/>
                    <measurement group_id="O3" value="88" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="18"/>
                    <measurement group_id="O2" value="53" spread="15"/>
                    <measurement group_id="O3" value="67" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Role Limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="27"/>
                    <measurement group_id="O2" value="79" spread="31"/>
                    <measurement group_id="O3" value="90" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Role Limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="24"/>
                    <measurement group_id="O2" value="76" spread="34"/>
                    <measurement group_id="O3" value="81" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="18"/>
                    <measurement group_id="O2" value="56" spread="20"/>
                    <measurement group_id="O3" value="64" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="19"/>
                    <measurement group_id="O2" value="60" spread="17"/>
                    <measurement group_id="O3" value="61" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Physical Function</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.566</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Social Function</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Mental Health</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Pain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Change in Health</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Physical Role Limitation</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.841</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Mental Role Limitation</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Energy/Vitality</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <method>ANOVA</method>
            <method_desc>For the analysis of Health Perception</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Memory Recall</title>
        <description>testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Memory Recall</title>
          <description>testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0</description>
          <units>words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="2"/>
                    <measurement group_id="O2" value="7" spread="1"/>
                    <measurement group_id="O3" value="6" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated VO2 Max</title>
        <description>VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male)</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated VO2 Max</title>
          <description>VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male)</description>
          <units>millilitres/kilogram/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="6.5"/>
                    <measurement group_id="O2" value="37.6" spread="7.2"/>
                    <measurement group_id="O3" value="38.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physical Function-&quot;Get up and go&quot; Test</title>
        <description>participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded.</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function-&quot;Get up and go&quot; Test</title>
          <description>participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="0.77"/>
                    <measurement group_id="O2" value="6.23" spread="0.59"/>
                    <measurement group_id="O3" value="5.87" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ankle Brachial Pressure Index (ABPI)</title>
        <description>ratio of blood pressure in left arm and right ankle</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Ankle Brachial Pressure Index (ABPI)</title>
          <description>ratio of blood pressure in left arm and right ankle</description>
          <units>ABPI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.16"/>
                    <measurement group_id="O2" value="1.08" spread="0.18"/>
                    <measurement group_id="O3" value="1.13" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Memory Recall</title>
        <description>testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds).
Maximum= 10 words, minimum = no words</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Memory Recall</title>
          <description>testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds).
Maximum= 10 words, minimum = no words</description>
          <units>words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1"/>
                    <measurement group_id="O2" value="5" spread="2"/>
                    <measurement group_id="O3" value="5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.513</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Executive Function (Verbal Fluency Test)</title>
        <description>written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals.
Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F</description>
        <time_frame>Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Assessment</title>
            <description>on entry to trial</description>
          </group>
          <group group_id="O2">
            <title>After 6 Week Control Period</title>
            <description>repeat assessment after 6 weeks of no intervention</description>
          </group>
          <group group_id="O3">
            <title>After HIT Assessment</title>
            <description>final assessment within 1 week of completing 6 weeks of HIT</description>
          </group>
        </group_list>
        <measure>
          <title>Executive Function (Verbal Fluency Test)</title>
          <description>written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals.
Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F</description>
          <units>words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="4"/>
                    <measurement group_id="O2" value="12" spread="4"/>
                    <measurement group_id="O3" value="11" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High-intensity Interval Training (HIT)</title>
          <description>6 week control period with no intervention then 6 weeks of twice weekly HIT
High-intensity Interval Training: 2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&amp;6, 8 sprints in sessions 7&amp;8, 9 sprints in sessions 9&amp;10 and 10 sprints in sessions 11&amp;12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>occurred at home during 6 week period of HIT intervention. Cardiologist concluded HIT had not contributed to his infarction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Niels Vollaard</name_or_title>
      <organization>University of Striling</organization>
      <phone>+441786466488</phone>
      <email>n.vollaard@stir.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

